Xeureka & UBE launch joint cancer drug discovery program
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
The update promises to revolutionize laboratory workflows by optimizing resources
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Patients with BRCA mutations often face aggressive disease and poor prognosis
Subscribe To Our Newsletter & Stay Updated